Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion type Assertion NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_head.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_provenance.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion evidence source_evidence_literature NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_provenance.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion SIO_000772 19424623 NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_provenance.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion wasDerivedFrom befree-2016 NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_provenance.
- NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_assertion wasGeneratedBy ECO_0000203 NP737410.RACZDfgTVTuSTwgiVYF-HhjNVdHQ10EoHE0Kle_TcB714130_provenance.